[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GLSMED Learning Health S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100617284","prospective-risk-evaluation-and-detection-of-crohns-disease-in-first-degree-relatives-100617284",false,"NCT07316621","Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives","PREDICT-CD","Inclusion Criteria:\n\n* Male or female participants, between 16 and 35 years old\n* FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD\n* Participants able to understand the information provided to them and to give written informed assent or consent for the study.\n\nExclusion Criteria:\n\n* Prior diagnosis of IBD\n* Any legal or medical condition that limits the information and participation in the study\n* Inability to verify CD diagnosis in the proband\n* Participants unwilling or unable to provide informed written consent\n* Participants unwilling or unable to donate blood for serum",true,"ALL","16 Years","35 Years",{"count":21,"type":22},10000,"ESTIMATED","OBSERVATIONAL","The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease.\n\nThis study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland.\n\nTo achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions.\n\nAt the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.",[26],"Crohn Disease (CD)","RECRUITING","2026-07-27",{"date":30,"type":31},"2026-07-29","ACTUAL",{"date":33,"type":31},"2026-04-01",{"date":35,"type":22},"2029-12-31",{"name":37,"class":38},"GLSMED Learning Health S.A.","OTHER",10,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100571976","glycan-supplementation-on-a-human-model-of-crohns-disease-initiation-and-progression-100571976","NCT06727253","Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression","GlycanTrigger - WP4: Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression: a Pilot Trial","Inclusion Criteria:\n\n* Male or female between 18 and 75 years old (inclusive) able to provide oral and written informed consent for participation in the study\n* Confirmed diagnosis of ileal or ileocolonic CD (according to ECCO guidelines)\n* Patients submitted to ileal and ileocecal resection for removing the diseased segment of the bowel.\n\nExclusion Criteria:\n\n* Diagnosis of indeterminate colitis, ulcerative colitis or microscopic colitis (collagenous colitis or lymphocytic colitis)\n* Patients receiving antibiotics, aminosalicylates, thiopurines, methotrexate, biologics or small molecules after surgery for postoperative recurrence\n* Patients with previous ICR or ileal resection due to CD, unless the treating physician does not intend to start other prophylactic therapy apart from the glycan supplement within the first 6 months following surgery\n* Pregnant or lactating women\n* Documented allergy to shellfish, glycans or glycans derivatives\n* History of dysplasia on colonic biopsy\n* Presence of, or history of cancer, except for skin cancer\n* History of poorly controlled type 1 or type 2 diabetes (HbA1c\\>8% or recurrent episodes of hyperglycaemic crisis such as diabetic ketoacidosis or hyperglycaemic hyperosmolar state)\n* Patients with known bleeding disorders (e.g. haemophilia or thrombocytopenia) or anticoagulation therapy (e.g. warfarin or direct oral anticoagulants)\n* Any physical or mental condition which would interfere with the ability to provide written and oral free informed consent or limit the study participation, collection of data, or study completion as determined by the Investigator\n* Unwillingness or inability to follow the procedures outlined in the protocol.","18 Years","75 Years",{"count":50,"type":22},30,"INTERVENTIONAL",[53],"NA","The overall aim of this proof-of-concept trial is to investigate the effect of an orally administered glycan on the modulation of the dysregulation of host-microbiome interactions and its effect on the mucosal immune response. Post-operative Crohn's Disease patients will be used as a representative model to mimic the immunopathogenic pathway of health-to-disease transition. Changes in gut glycocalyx seem to be a primary event involved in the disruption of the interaction between the microbiota and the host immune system. Thus, this study aims to assess the effect of the modulation of the glycome on the microbial and immunological changes that contribute to disease development.",[26],"2025-07-31",{"date":58,"type":31},"2025-08-05",{"date":60,"type":31},"2025-05-26",{"date":62,"type":22},"2028-12-01",{"name":37,"class":38},1,""]